High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma

放射性核素治疗 副神经节瘤 医学 嗜铬细胞瘤 神经内分泌肿瘤 肿瘤科 放射治疗 靶向治疗 内科学 癌症 放射科
作者
Karel Pacák,David Taïeb,Jorge A. Carrasquillo,Daniel A. Pryma,Mayank Patel,Corina Millo,Wouter W. de Herder,Jaydira Del Rivero,Joakim Crona,Barry L. Shulkin,Irene Virgolini,Alice Chen,Bhagwant Rai Mittal,Sandip Basu,Joseph S. Dillon,Thomas A. Hope,Carina Marí Aparici,Andrei Iagaru,Rodney J. Hicks,Anca M. Avram,Jonathan Strosberg,A. Cahid Civelek,Frank I. Lin,Neeta Pandit‐Taskar
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:27 (11): 2989-2995 被引量:50
标识
DOI:10.1158/1078-0432.ccr-20-3703
摘要

Abstract Targeted radionuclide therapies (TRT) using 131I-metaiodobenzylguanidine (131I-MIBG) and peptide receptor radionuclide therapy (177Lu or 90Y) represent several of the therapeutic options in the management of metastatic/inoperable pheochromocytoma/paraganglioma. Recently, high-specific-activity-131I-MIBG therapy was approved by the FDA and both 177Lu-DOTATATE and 131I-MIBG therapy were recommended by the National Comprehensive Cancer Network guidelines for the treatment of metastatic pheochromocytoma/paraganglioma. However, a clinical dilemma often arises in the selection of TRT, especially when a patient can be treated with either type of therapy based on eligibility by MIBG and somatostatin receptor imaging. To address this problem, we assembled a group of international experts, including oncologists, endocrinologists, and nuclear medicine physicians, with substantial experience in treating neuroendocrine tumors with TRTs to develop consensus and provide expert recommendations and perspectives on how to select between these two therapeutic options for metastatic/inoperable pheochromocytoma/paraganglioma. This article aims to summarize the survival outcomes of the available TRTs; discuss personalized treatment strategies based on functional imaging scans; address practical issues, including regulatory approvals; and compare toxicities and risk factors across treatments. Furthermore, it discusses the emerging TRTs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
menga完成签到,获得积分20
1秒前
小猪干脆面完成签到,获得积分10
2秒前
伯赏若枫完成签到,获得积分10
3秒前
852应助强健的雅霜采纳,获得10
3秒前
Hui_2023发布了新的文献求助10
3秒前
轻松新之发布了新的文献求助10
3秒前
cjl完成签到,获得积分20
3秒前
壮观复天完成签到,获得积分10
3秒前
malele发布了新的文献求助50
4秒前
dyc完成签到 ,获得积分10
5秒前
5秒前
5秒前
上进生发布了新的文献求助10
5秒前
皮皮鲁完成签到,获得积分10
6秒前
言言发布了新的文献求助10
6秒前
6秒前
6秒前
上官若男应助Ray采纳,获得10
7秒前
7秒前
7秒前
8秒前
8秒前
Jasper应助落寞平萱采纳,获得10
9秒前
不配.应助pura卷卷采纳,获得20
9秒前
Leo发布了新的文献求助10
9秒前
爆米花应助胖虎啊采纳,获得10
10秒前
热情冰凡发布了新的文献求助10
10秒前
10秒前
ikuya完成签到,获得积分20
10秒前
热心绿柏发布了新的文献求助10
10秒前
南昌黑人完成签到,获得积分10
11秒前
李爱国应助zhangpeng采纳,获得10
11秒前
顾矜应助上进生采纳,获得10
11秒前
宝宝完成签到 ,获得积分10
12秒前
12秒前
12秒前
13秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3156110
求助须知:如何正确求助?哪些是违规求助? 2807513
关于积分的说明 7873605
捐赠科研通 2465844
什么是DOI,文献DOI怎么找? 1312456
科研通“疑难数据库(出版商)”最低求助积分说明 630107
版权声明 601905